Annandale Capital’s Cue Biopharma CUE Stock Holding History

Annandale Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,167	Closed	-$172K	–	140
2023 Q4	$172K	Hold	2,167	–	–	0.03%	132
2023 Q3	$150K	Hold	2,167	–	–	0.04%	123
2023 Q2	$237K	Hold	2,167	–	–	0.07%	115
2023 Q1	$232K	Hold	2,167	–	–	0.07%	110
2022 Q4	$185K	Hold	2,167	–	–	0.06%	117
2022 Q3	$145K	Buy	+2,167	New	+$186K	0.05%	121

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Annandale Capital's CUE Position: Q1 2024 in Review

Annandale Capital sold out of Cue Biopharma (CUE) in Q1 2024, closing a stake of 2,167 shares — an estimated $172K sold.

Annandale Capital first reported a position in CUE in Q3 2022 and held it in 6 quarters. The position peaked at $237K in Q2 2023. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2024.

Annandale Capital reported no remaining Cue Biopharma position as of Q1 2024 after selling out during the quarter.
Annandale Capital sold 2,167 Cue Biopharma shares in Q1 2024, an estimated $172K.
Annandale Capital first reported a position in Cue Biopharma in Q3 2022 and held it in 6 quarters.
Annandale Capital's Cue Biopharma position peaked at $237K in Q2 2023.
74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2024.

Based on Annandale Capital's 13F filing for Q1 2024, filed 15 May 2024.